FTH compared with DSGN: revenue, margins and what each company keeps, and the suppliers and customers both name

FTHFaeth Therapeutics, Inc.

Mkt capRevenueRevenue

DSGNDesign Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

FTHFaeth Therapeutics, Inc.

DSGNDesign Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

FTH1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−6.73%—

DSGN

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±28.1%▲+4.76%×0.17

Apr 29 '26±29.8%▲+23.26%×0.78

= impliedFTH realized, solidDSGN realized, hatchedOne scale, both sides: full bar = 41%× = |realized| ÷ impliedSource: market data

Q1 FY26

±38.8%

▼−3.66%

×0.10

Nov 6 '25±40.6%▲+4.89%×0.12

FTHFaeth Therapeutics, Inc.

18.21· pre 18.32· delayed

Mkt cap$483.0M

DSGNDesign Therapeutics, Inc.

10.66· pre 10.66· delayed

Pre-marketOct 30 '26delayed

Mkt cap$668.4M

Compare

Pre-marketOct 30 '26delayed

FTHFaeth Therapeutics, Inc.

DSGNDesign Therapeutics, Inc.

18.21pre 18.32delayed

Price

10.66pre 10.66delayed

$483.0M

Mkt cap

$668.4M

FTH18.21vsDSGN10.66Pre-marketOct 30 '26delayed